Search

Your search keyword '"Giridharan P"' showing total 74 results

Search Constraints

Start Over You searched for: Author "Giridharan P" Remove constraint Author: "Giridharan P" Journal blood Remove constraint Journal: blood
74 results on '"Giridharan P"'

Search Results

1. Treatment Patterns and Outcomes of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Treated with Hypomethylating Agents (HMA) in the United States (US)

2. Treatment Patterns and Outcomes of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Treated with Hypomethylating Agents (HMA) in the United States (US)

Catalog

Books, media, physical & digital resources

3. Cytopenia Management in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Azacitidine in the VIALE-A Study

4. Cytopenia Management in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Azacitidine in the VIALE-A Study

5. Acquired copy number alterations of miRNA genes in acute myeloid leukemia are uncommon

6. The phenotype of human STK4 deficiency

7. The phenotype of human STK4 deficiency

8. Complete characterization of the microRNAome in a patient with acute myeloid leukemia

9. Complete characterization of the microRNAome in a patient with acute myeloid leukemia

10. Use of Venetoclax (VEN) and Hypomethylating Agents (HMA) in Newly Diagnosed Acute Myeloid Leukemia (AML) in the United States (US) - Real World (RW) Response, Treatment Duration, Dose and Schedule Modifications

11. Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia Harboring Heterogeneous Genomic Profiles Respond to Venetoclax in Combination with Chemotherapy

12. Venetoclax Alone or in Combination with Chemotherapy: Responses in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia with Heterogeneous Genomic Profiles

13. Venetoclax Alone or in Combination with Chemotherapy: Responses in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia with Heterogeneous Genomic Profiles

15. The Presence of Philadelphia Chromosome Does Not Confer Poor Prognosis in Adult Pre-B Acute Lymphoblastic Leukemia in the Tyrosine Kinase Inhibitor Era - a Surveillance, Epidemiology, and End Results Database Analysis

16. Comprehensive Characterization of Transposable Elements in the Acute Myeloid Leukemia Transcriptome

17. Metabolic Changes in Aging Bone Marrow

18. Immune Clearance of Senescent Cells Via Activation of Endogenous Retroviruses and the Viral Recognition Pathway

19. Novel Role of CEBPβ As a Transcriptional Repressor of Transposable Elements

22. Safety and Pharmacokinetics of the Complement Inhibitor TT30 in a Phase I Trial for Untreated PNH Patients

24. Presence of Primary Cilia in Human Hematopoietic System

26. The Hedgehog Regulated Transcription Factor and Tumor Suppressor, Gli3, Regulates Hematopoietic Stem Cell Number, Self-Renewal and Differentiation

30. Microtransplantation: HLA-Mismatched Allogeneic Cellular Therapy of Acute Myeloid Leukemia (HMMACT)

31. Deficiency Of JAGN1 Causes Severe Congenital Neutropenia Associated With Defective Secretory Pathway and Aberrant Myeloid Cell Homeostasis

33. The Role Of Early TP53 Mutations On The Evolution Of Therapy-Related AML

35. DNA Methylation Changes In Aging Human CD34+ Cells Coincide With Hotspots Of Disordered Methylation In AML At Imprinted and Allelically Methylated Regions

36. Dysregulation and Recurrent Mutation Of miRNA-142 In De NovoAML

37. Deficiency Of JAGN1 Causes Severe Congenital Neutropenia Associated With Defective Secretory Pathway and Aberrant Myeloid Cell Homeostasis

38. The Role Of Early TP53 Mutations On The Evolution Of Therapy-Related AML

39. Whole Genome Sequencing of Therapy-Related Acute Myeloid Leukemia

43. The Phenotype of Human STK4 Deficiency

44. A Phase 1 Study of Concomitant High Dose Lenalidomide and 5-Azacytidine Induction in the Treatment of Acute Myeloid Leukemia,

45. Phase I Study of Cladribine (2-chlorodeoxyadenosie), Cytarabine and G-CSF Based Induction Therapy (CLAG) with ATRA (All-trans retinoic acid) and Midostaurin for Relapsed/Refractory AML,

46. G6PC3 Deficiency Associated with Congenital Neutropenia and Enterocolitis

47. G6PC3 Deficiency Associated with Congenital Neutropenia and Enterocolitis

48. The Phenotype of Human STK4 Deficiency